These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30298903)

  • 1. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
    Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
    Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
    [No Abstract]   [Full Text] [Related]  

  • 2. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
    Reddy SA
    Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin in combination with low-dose methotrexate in advanced-stage mycosis fungoides and Sézary syndrome.
    Cieza-Díaz DE; Machan S; Prieto-Torres L; Requena L; Córdoba R
    Dermatol Ther; 2021 May; 34(3):e14952. PubMed ID: 33724662
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C; Zain J; Rosen ST
    Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
    Jfri A; Smith JS; Larocca C
    J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome.
    Kuzel TM
    Dermatol Ther; 2003; 16(4):355-61. PubMed ID: 14686979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30
    Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
    J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
    Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
    Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
    Durgin JS; Weiner DM; Wysocka M; Rook AH
    J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
    Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab induced complete remission of romidepsin-refractory large cell transformation of mycosis fungoides.
    Kwong YL
    Ann Hematol; 2014 Apr; 93(4):713-4. PubMed ID: 23934231
    [No Abstract]   [Full Text] [Related]  

  • 17. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
    Joshi TP; Duvic M
    J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
    Geller S; Lebowitz E; Pulitzer MP; Horwitz SM; Moskowitz AJ; Dusza S; Myskowski PL
    J Am Acad Dermatol; 2020 Aug; 83(2):430-439. PubMed ID: 31499157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.
    Quaglino P; Fava P; Pileri A; Grandi V; Sanlorenzo M; Panasiti V; Guglielmo A; Alberti-Violetti S; Novelli M; Astrua C; Rubatto M; Tonella L; Berti E; Pimpinelli N; Osella Abate S; Fierro MT; Vermeer M; Scarisbrick JJ; Ribero S
    J Invest Dermatol; 2021 Mar; 141(3):484-495. PubMed ID: 33162051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.